N@N

Phil Nadeau Maintained (VRTX) at Buy with Increased Target to $310 on, Jun 13th, 2022

Phil Nadeau of Cowen & Co., Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $305 to $310 on, Jun 13th, 2022.

Phil has made no other calls on VRTX in the last 4 months.

There are 12 other peers that have a rating on VRTX. Out of the 12 peers that are also analyzing VRTX, 6 agree with Phil's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $267 on, Sunday, June 12th, 2022
• David Risinger of "SVB Leerink" Initiated at Hold and Held Target at $265 on, Monday, May 23rd, 2022
• Do Kim of "Piper Sandler" Maintained at Hold with Decreased Target to $242 on, Friday, May 6th, 2022
• Brian Skorney of "Baird" Downgraded from Buy to Hold on, Friday, May 6th, 2022
• Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $240 on, Thursday, May 5th, 2022
• Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold and Held Target at $250 on, Tuesday, May 3rd, 2022

These are the ratings of the 6 analyists that currently disagree with Phil

---

• Jason McCarthy of "Maxim Group" Upgraded from Hold to Strong Buy and Held Target at $325 on, Wednesday, June 1st, 2022
• Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $278 on, Tuesday, May 24th, 2022
• Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $305 on, Friday, May 6th, 2022
• Gena Wang of "Barclays" Maintained at Buy and Held Target at $291 on, Thursday, May 5th, 2022
• Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $322 on, Wednesday, April 27th, 2022
• Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022

Contributing Sources

---